| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
CD2: ABCIXIMAB IN PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY: A MULTICENTER OBSERVATIONAL STUDY
|
Vlasses, PH
|
|
1999
|
2 |
3 |
p. 129-
1 p.
|
artikel
|
| 2 |
CD3: EXCESS STROKE AMONG HYPERTENSIVE MEN AND WOMEN ATTRIBUTABLE TO UNDERTREATMENT OF HYPERTENSION
|
Klungel, OH
|
|
1999
|
2 |
3 |
p. 129-130
2 p.
|
artikel
|
| 3 |
CD1: HOSPITAL UTILIZATION AND COST AMONG PATIENTS WITH NONISCHEMIC HEART FAILURE IN THE FIRST PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY (PRAISE)
|
Radensky, PW
|
|
1999
|
2 |
3 |
p. 129-
1 p.
|
artikel
|
| 4 |
CD4: LEFT VENTRICULAR SYSTOLIC FUNCTION AND 90-DAY HOSPITAL READMISSION IN CONGESTIVE HEART FAILURE PATIENTS: IMPLICATIONS FOR DISEASE MANAGEMENT
|
Wang, AY
|
|
1999
|
2 |
3 |
p. 130-
1 p.
|
artikel
|
| 5 |
DISCLOSURE INFORMATION
|
|
|
1999
|
2 |
3 |
p. 240-245
6 p.
|
artikel
|
| 6 |
DM4: COST-EFFECTIVENESS OF OCCUPATIONAL THERAPY ON HEALTHY ELDERLY PEOPLE
|
Luo, R
|
|
1999
|
2 |
3 |
p. 136-137
2 p.
|
artikel
|
| 7 |
DM3: IMPLEMENTATION OF NATIONAL CHOLESTEROL GUIDELINES: A MULTIDISCIPLINARY APPROACH TO HYPERLIPIDEMIA DISEASE MANAGEMENT
|
Borenstein, J
|
|
1999
|
2 |
3 |
p. 136-
1 p.
|
artikel
|
| 8 |
DM2: MEASURING THE EFFECTIVENESS OF A DIABETES DISEASE MANAGEMENT PROGRAM
|
Jackson, A
|
|
1999
|
2 |
3 |
p. 135-136
2 p.
|
artikel
|
| 9 |
DM1: RANDOMIZED EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR DYSPEPSIA IN A MANAGED CARE SETTING
|
Segal, R
|
|
1999
|
2 |
3 |
p. 135-
1 p.
|
artikel
|
| 10 |
DP1: EFFECT OF DEMOGRAPHICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM
|
Momin, SR
|
|
1999
|
2 |
3 |
p. 140-
1 p.
|
artikel
|
| 11 |
DP2: THE RELATIONSHIP BETWEEN PAYER TYPE AND HOSPITALIZATION RATES FOR ASTHMATICS SUBSEQUENT TO AN EMERGENCY ROOM VISIT
|
Stanford, RH
|
|
1999
|
2 |
3 |
p. 140-141
2 p.
|
artikel
|
| 12 |
DP4: USING COST OF ILLNESS STUDIES IN HEALTHCARE POLICY-MAKING
|
Bloom, BS
|
|
1999
|
2 |
3 |
p. 141-
1 p.
|
artikel
|
| 13 |
DP3: USING SIMULATION MODELING TECHNIQUES TO FACILITATE THE MANAGEMENT OF THE WAITING LIST FOR LIVER TRANSPLANTATION
|
Ratcliffe, J
|
|
1999
|
2 |
3 |
p. 141-
1 p.
|
artikel
|
| 14 |
ER4: MODELING PHARMACOECONOMIC ANALYSES WITH DISTRIBUTIONS OF RESULTS FROM TRIALS
|
Smith, D
|
|
1999
|
2 |
3 |
p. 139-140
2 p.
|
artikel
|
| 15 |
ER3: OSTEOPOROSIS MARKOV MODEL: EVALUATING THE IMPACT OF DISCOUNTING AND AGE-ADJUSTED FRACTURE RATES ON COST-EFFECTIVENESS RATIOS AND MARKOV ANALYSIS
|
Keys, P
|
|
1999
|
2 |
3 |
p. 139-
1 p.
|
artikel
|
| 16 |
ER2: PRICE ELASTICITY OF PEOPLE'S WILLINGNESS TO PAY IN PATIENTS WITH URINARY INCONTINENCE
|
Budhiarso, I
|
|
1999
|
2 |
3 |
p. 139-
1 p.
|
artikel
|
| 17 |
ER1: THE APPLICATION OF MULTILEVEL MODELING AND CLUSTER ANALYSIS TO MULTINATIONAL ECONOMIC EVALUATION DATA
|
Pang, F
|
|
1999
|
2 |
3 |
p. 138-139
2 p.
|
artikel
|
| 18 |
ID4: A COST ANALYSIS OF LEVOFLOXACIN VERSUS CEFTRIAXONE IN ADULT INPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
|
Rittenhouse, BE
|
|
1999
|
2 |
3 |
p. 135-
1 p.
|
artikel
|
| 19 |
ID3: ADDITIONAL ANTIBIOTIC UTILIZATION IN A RANDOMIZED TRIAL OF CLARITHROMYCIN (CLARI) COMPARED WITH AZITHROMYCIN (AZI) FOR THE TREATMENT OF S. PYOGENES PHARYNGITIS/TONSILLITIS
|
Chang, RJ
|
|
1999
|
2 |
3 |
p. 134-135
2 p.
|
artikel
|
| 20 |
ID2: CHRONIC HEPATITIS C: COST-EFFECTIVENESS OF INTERFERON AND RIBAVIRIN
|
Singer, ME
|
|
1999
|
2 |
3 |
p. 134-
1 p.
|
artikel
|
| 21 |
ID1: ESTIMATING THE COST-EFFECTIVENESS OF ANTIBIOTIC TREATMENT FOR ACUTE OTITIS MEDIA USING INSTRUMENTAL VARIABLE ESTIMATION TECHNIQUES
|
Brooks, JM
|
|
1999
|
2 |
3 |
p. 133-134
2 p.
|
artikel
|
| 22 |
ND3: AN OUTCOMES MEASURE FOR NON-INSTITUTIONALIZED SCHIZOPHRENIC CONSUMERS
|
Barr, JT
|
|
1999
|
2 |
3 |
p. 131-
1 p.
|
artikel
|
| 23 |
ND4: ASSESSING UTILITIES FOR DEPRESSION OUTCOMES: PREFERENCES OF DEPRESSED PATIENTS AND THE GENERAL PUBLIC
|
Gonzales, J
|
|
1999
|
2 |
3 |
p. 131-132
2 p.
|
artikel
|
| 24 |
ND1: INPATIENT COST AND RESOURCE UTILIZATION FOR PARKINSON'S DISEASE
|
Doshi, DP
|
|
1999
|
2 |
3 |
p. 130-131
2 p.
|
artikel
|
| 25 |
ND2: POTENTIAL SAVINGS IN THE COST OF TREATING ALZHEIMER'S DISEASE: PATIENT TREATMENT WITH RIVASTIGMINE
|
Hauber, AB
|
|
1999
|
2 |
3 |
p. 131-
1 p.
|
artikel
|
| 26 |
PAD6: ASSESSMENT OF THE ECONOMIC AND HUMANISTIC OUTCOMES OF THE WEST VIRGINIA MEDICAID'S PRIOR AUTHORIZATION POLICY FOR NSAIDS
|
Momani, A
|
|
1999
|
2 |
3 |
p. 191-192
2 p.
|
artikel
|
| 27 |
PAD4: CLINICALLY MEANINGFUL IMPROVEMENT OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AMONG OSTEOARTHRITIS (OA) PATIENTS
|
Zhao, SZ
|
|
1999
|
2 |
3 |
p. 191-
1 p.
|
artikel
|
| 28 |
PAD1: EFFICACY OF AN INTERVENTION TO RATIONALIZE PRESCRIBING OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
|
Elkharrat, D
|
|
1999
|
2 |
3 |
p. 189-190
2 p.
|
artikel
|
| 29 |
PAD8: INTERPRETATION OF HAQ DISABILITY INDEX IMPROVEMENT AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS IN RANDOMIZED CLINICAL TRIALS
|
Zhao, SZ
|
|
1999
|
2 |
3 |
p. 192-
1 p.
|
artikel
|
| 30 |
PAD2: OPTIMIZATION OF AN HMO'S NSAID PORTFOLIO FOLLOWING THE INTRODUCTION OF CELECOXIB
|
Pettitt, AD
|
|
1999
|
2 |
3 |
p. 190-
1 p.
|
artikel
|
| 31 |
PAD7: PHARMACOEPIDEMIOLOGY OF INITIAL DISEASE MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY IN A MANAGED CARE ORGANIZATION (MCO)
|
Griffiths, RI
|
|
1999
|
2 |
3 |
p. 192-
1 p.
|
artikel
|
| 32 |
PAD3: RESPONSIVENESS OF WOMAC IMPROVEMENT TO PATIENTS' AND PHYSICIANS' GLOBAL ASSESSMENT (PtGA & PhGA) OF IMPROVEMENT AMONG OSTEOARTHRITIS PATIENTS (OA)
|
Zhao, SZ
|
|
1999
|
2 |
3 |
p. 190-191
2 p.
|
artikel
|
| 33 |
PAD5: RETROSPECTIVE EVALUATION OF CONCOMITANT GASTROINTESTINAL DRUG USE WITH NSAID THERAPY AMONG PATIENTS WITH ARTHRITIS
|
Lapane, K
|
|
1999
|
2 |
3 |
p. 191-
1 p.
|
artikel
|
| 34 |
PCD8: AN ANALYSIS OF RESEARCH AND POLICYRELEVANT CHARACTERISTICS OF QUALITY OF LIFE ASSESSMENTS IN PROSTATE CANCER
|
Sommers, SD
|
|
1999
|
2 |
3 |
p. 195-196
2 p.
|
artikel
|
| 35 |
PCD6: COMPARISON OF THE McMASTER'S HEALTH UTILITIES INDEX-MARK III AND THE EUROQOL-5D IN A SURGICAL BREAST CANCER POPULATION
|
Namjoshi, MA
|
|
1999
|
2 |
3 |
p. 194-195
2 p.
|
artikel
|
| 36 |
PCD11: COST-EFFECTIVENESS OF THE THERAPY WITH IODINE 125-SEED IMPLANTATION IN PATIENTS WITH STAGE T1 AND T2 PROSTATE CARCINOMA IN COMPARISON TO TOTAL PROSTATECTOMY AND BEAM RADIATION IN 3D-TECHNIQUE
|
Thomas, J
|
|
1999
|
2 |
3 |
p. 196-197
2 p.
|
artikel
|
| 37 |
PCD12: COST OF MANAGING MUCOSITIS AND XEROSTOMIA IN HEAD AND NECK CANCER PATIENTS UNDERGOING CHEMORADIOTHERAPY (CRT) OR RADIATION (RT)
|
Bonomi, AE
|
|
1999
|
2 |
3 |
p. 197-
1 p.
|
artikel
|
| 38 |
PCD3: COSTS AND OUTCOMES OF HOME VERSUS HOSPITAL-BASED TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY PATIENTS
|
Raisch, DW
|
|
1999
|
2 |
3 |
p. 193-194
2 p.
|
artikel
|
| 39 |
PCD2: COSTS ASSOCIATED WITH CHEMOTHERAPY-INDUCED TOXICITIES: A REVIEW OF THE LITERATURE
|
Jackson, S
|
|
1999
|
2 |
3 |
p. 193-
1 p.
|
artikel
|
| 40 |
PCD10: DIFFERENCES IN END-OF-LIFE MEDICAL CARE COSTS FOR PROSTATE CANCER PATIENTS: RESULTS FROM THE CaPSURE DATABASE
|
Lubeck, DP
|
|
1999
|
2 |
3 |
p. 196-
1 p.
|
artikel
|
| 41 |
PCD1: DIRECT AND INDIRECT COSTS OF CHEMOTHERAPY-INDUCED TOXICITY
|
Calhoun, E
|
|
1999
|
2 |
3 |
p. 193-
1 p.
|
artikel
|
| 42 |
PCD7: INITIAL, MAINTENANCE, AND TERMINAL CARE COSTS OF BREAST CANCER TREATMENT
|
Noe, LL
|
|
1999
|
2 |
3 |
p. 195-
1 p.
|
artikel
|
| 43 |
PCD13: PATIENT BENEFIT QUESTIONNAIRE (PBQ) FOR XEROSTOMIA: DEVELOPMENT AND VALIDATION REPORT
|
Mackowiak, JI
|
|
1999
|
2 |
3 |
p. 197-
1 p.
|
artikel
|
| 44 |
PCD5: RELIABILITY AND VALIDITY OF THE BREAST EVALUATION QUESTIONNAIRE (BEQ): AN OUTCOME MEASURE FOR BREAST IMPLANT STUDIES
|
Lenderking, WR
|
|
1999
|
2 |
3 |
p. 194-
1 p.
|
artikel
|
| 45 |
PCD4: THE VALUE OF HOME CARE IN METASTATIC BREAST CANCER MANAGEMENT: MODELING ORAL VERSUS INTRAVENOUS CHEMOTHERAPY AT HOME AND AT AN OUTPATIENT CLINIC
|
Mathes, A
|
|
1999
|
2 |
3 |
p. 194-
1 p.
|
artikel
|
| 46 |
PCD9: UTILIZATION OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) TREATMENTS AMONG PROSTATE CANCER PATIENTS IN CaPSURE
|
Lubeck, DP
|
|
1999
|
2 |
3 |
p. 196-
1 p.
|
artikel
|
| 47 |
PCP8: ASSESSMENT OF SURGICAL ANESTHESIA AND POSTOPERATIVE ANALGESIA USING A PAIN VISUAL ANALOG SCALE
|
Yfantopoulos, Y
|
|
1999
|
2 |
3 |
p. 208-
1 p.
|
artikel
|
| 48 |
PCP1: A THREE-PHASED DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOID THERAPY FOR CHRONIC PAIN
|
Neighbors, DM
|
|
1999
|
2 |
3 |
p. 205-
1 p.
|
artikel
|
| 49 |
PCP7: COSTS AND OUTCOMES OF REGIONAL VERSUS GENERAL VERSUS COMBINATION ANESTHESIA AND ANALGESIA TECHNIQUES IN GREEK PATIENTS UNDERGOING HIP ARTHROPLASTY
|
Yfantopoulos, Y
|
|
1999
|
2 |
3 |
p. 207-208
2 p.
|
artikel
|
| 50 |
PCP2: IMPACT OF PATIENT EDUCATION ON QUALITY OF LIFE IN HEADACHE TREATMENT
|
Solomon, GD
|
|
1999
|
2 |
3 |
p. 205-206
2 p.
|
artikel
|
| 51 |
PCP4: LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE (PPMQ) IN 16 LANGUAGES
|
Conway, K
|
|
1999
|
2 |
3 |
p. 206-207
2 p.
|
artikel
|
| 52 |
PCP6: OPIOID ANALGESICS USE IN PATIENTS WITH NONMALIGNANT PAIN: SELECTING AN APPROPRIATE COMPARISON GROUP
|
Loughlin, JE
|
|
1999
|
2 |
3 |
p. 207-
1 p.
|
artikel
|
| 53 |
PCP9: THE ANALGESIC EFFICACY AND THERAPEUTIC ONSET OF ANALGESIA OF INTRAVENOUS AND INTRAMUSCULAR KETOROLAC (15 MG AND 30 MG), AND ORAL IBUPROFEN 800 MG IN THE EMERGENCY ROOM: A COMPARATIVE STUDY
|
Habib, M
|
|
1999
|
2 |
3 |
p. 208-209
2 p.
|
artikel
|
| 54 |
PCP3: THE ECONOMIC COST OF ACETAMINOPHENRELATED LIVER TOXICITY TO THE CALIFORNIA MEDICAID PROGRAM
|
Menzin, J
|
|
1999
|
2 |
3 |
p. 206-
1 p.
|
artikel
|
| 55 |
PCP5: USE OF OPIOID ANALGESICS FOR NONMALIGNANT PAIN CONDITIONS: A CROSS-SECTIONAL CHARACTERIZATION
|
Sesti, AM
|
|
1999
|
2 |
3 |
p. 207-
1 p.
|
artikel
|
| 56 |
PCVD1: A COMPARISON OF THE EMEA AND FDA DRAFT GUIDELINES IN CONGESTIVE HEART FAILURE (CHF) WITH PARTICULAR REFERENCE TO QUALITY OF LIFE (QOL) OUTCOMES
|
Wiklund, I
|
|
1999
|
2 |
3 |
p. 163-
1 p.
|
artikel
|
| 57 |
PCVD4: AN ECONOMIC MODEL OF HYPERTENSION IN ONTARIO
|
Bentkover, JD
|
|
1999
|
2 |
3 |
p. 164-
1 p.
|
artikel
|
| 58 |
PCVD13: ASSESSING LIPID-LOWERING INTERVENTIONS IN MANAGED CARE SETTINGS
|
Felber, G
|
|
1999
|
2 |
3 |
p. 167-
1 p.
|
artikel
|
| 59 |
PCVD10: ATTAINMENT OF LIPID GOALS IN PATIENTS TREATED WITH HMG-COA REDUCTASE INHIBITORS: A RETROSPECTIVE STUDY
|
Nichol, MB
|
|
1999
|
2 |
3 |
p. 166-
1 p.
|
artikel
|
| 60 |
PCVD15: A UK PRIMARY CARE DATABASE (UKPCD): UK MEDIPLUS IS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE PREVALENCE OF PATIENTS WITH A HISTORY OF OBESITY OR OVERWEIGHT, THEIR TREATMENT, AND ASSOCIATED COMORBIDITIES
|
Starling, A
|
|
1999
|
2 |
3 |
p. 167-168
2 p.
|
artikel
|
| 61 |
PCVD3: COST-EFFECTIVENESS OF THROMBOLYTIC AGENTS IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
|
Kamath, T
|
|
1999
|
2 |
3 |
p. 163-164
2 p.
|
artikel
|
| 62 |
PCVD5: DELPHI PANEL SURVEY ON CURRENT HYPERTENSION TREATMENT PATTERNS
|
Richter, A
|
|
1999
|
2 |
3 |
p. 164-
1 p.
|
artikel
|
| 63 |
PCVD12: EFFECTS OF AN EDUCATIONAL CAMPAIGN ON MEDICATION USE FOR CORONARY ARTERY DISEASE (CAD)
|
Perry, CF
|
|
1999
|
2 |
3 |
p. 166-167
2 p.
|
artikel
|
| 64 |
PCVD11: FORMULARY ANALYSIS OF ANGIOTENSIN II ANTAGONISTS IN A UK TEACHING HOSPITAL
|
Wheeldon, N
|
|
1999
|
2 |
3 |
p. 166-
1 p.
|
artikel
|
| 65 |
PCVD2: HYPERTENSION DISEASE MANAGEMENT: A RANDOMIZED, COMPARATIVE TRIAL
|
Borenstein, J
|
|
1999
|
2 |
3 |
p. 163-
1 p.
|
artikel
|
| 66 |
PCVD7: IDENTIFICATION OF COMOROBIDITIES AMONG A HYPERTENSIVE POPULATION USING ADMINISTRITATIVE CLAIMS AND MEDICAL RECORDS DATA
|
Connors, H
|
|
1999
|
2 |
3 |
p. 164-165
2 p.
|
artikel
|
| 67 |
PCVD9: LEFT VENTRICULAR SYSTOLIC FUNCTION AND DRUG UTILIZATION AMONG HOSPITALIZED PATIENTS WITH CONGESTIVE HEART FAILURE
|
Wang, AY
|
|
1999
|
2 |
3 |
p. 165-166
2 p.
|
artikel
|
| 68 |
PCVD8: SELECTIVE USE OF CALCIUM ANTAGONISTS FOR HIGH-RISK HYPERTENSIVES
|
Leader, S
|
|
1999
|
2 |
3 |
p. 165-
1 p.
|
artikel
|
| 69 |
PCVD16: THE ECONOMIC AND HEALTH BENEFITS OF CONVERSION TO NORMAL SINUS RHYTHM
|
Caro, JJ
|
|
1999
|
2 |
3 |
p. 168-
1 p.
|
artikel
|
| 70 |
PCVD14: USE OF CONFIDENCE INTERVALS TO ESTIMATE THE COST-EFFECTIVENESS OF ABCIXIMAB
|
Reed, SO
|
|
1999
|
2 |
3 |
p. 167-
1 p.
|
artikel
|
| 71 |
PDD3: A COST-OF-TREATMENT MODEL FOR TYPE 2 DIABETES
|
Stephens, JM
|
|
1999
|
2 |
3 |
p. 198-199
2 p.
|
artikel
|
| 72 |
PDD4: DEVELOPMENT OF HEALTH STATE DESCRIPTIONS OF DIABETIC PERIPHERAL NEUROPATHY FOR A NEW UTILITY INSTRUMENT
|
Lew, DP
|
|
1999
|
2 |
3 |
p. 199-
1 p.
|
artikel
|
| 73 |
PDD1: DISEASE MANAGEMENT PATTERNS OF TYPE 2 DIABETIC PATIENTS IN AN ACADEMIC FAMILY MEDICINE CENTER
|
Longe, RL
|
|
1999
|
2 |
3 |
p. 198-
1 p.
|
artikel
|
| 74 |
PDD5: ONYCHOMYCOSIS AND ITS IMPACT ON SECONDARY INFECTION DEVELOPMENT IN THE DIABETIC POPULATION
|
Boyko, WL
|
|
1999
|
2 |
3 |
p. 199-
1 p.
|
artikel
|
| 75 |
PDD2: PSYCHOMETRIC PROPERTIES OF THE PATIENT BENEFIT QUESTIONNAIRE (PBQ) IN A COHORT OF DIABETIC PERIPHERAL NEUROPATHY (DPN) PATIENTS
|
Kirchdoerfer, LJ
|
|
1999
|
2 |
3 |
p. 198-
1 p.
|
artikel
|
| 76 |
PG11: COSTS AND PRACTICE PATTERNS ASSOCIATED WITH TREATING GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN A MANAGED CARE POPULATION
|
Nichol, MB
|
|
1999
|
2 |
3 |
p. 200-
1 p.
|
artikel
|
| 77 |
PG15: FACTORS INFLUENCING THE DURATION OF GI MEDICATION TREATMENT ASSOCIATED WITH NSAID-INDUCED GASTROPATHY
|
Wu, WK
|
|
1999
|
2 |
3 |
p. 201-
1 p.
|
artikel
|
| 78 |
PG12: OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN FOR H. PYLORI ERADICATION PRODUCES GREATEST COST SAVINGS IN MALAYSIAN DUODENAL ULCER PATIENTS
|
Conway, DP
|
|
1999
|
2 |
3 |
p. 200-
1 p.
|
artikel
|
| 79 |
PG13: PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS: HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE UK
|
Rolnick, M
|
|
1999
|
2 |
3 |
p. 200-201
2 p.
|
artikel
|
| 80 |
PG14: PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS: HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE USA
|
Rolnick, M
|
|
1999
|
2 |
3 |
p. 201-
1 p.
|
artikel
|
| 81 |
PG17: RATE OF GI DISTRESS AMONG PATIENTS TREATED WITH CELECOXIB, PLACEBO, OR NSAIDs USING THREE DIFFERENT STATISTICAL METHODS
|
Zhao, SZ
|
|
1999
|
2 |
3 |
p. 202-
1 p.
|
artikel
|
| 82 |
PG16: SEQUENCING OF TREATMENTS IN VARICEAL BLEEDING
|
Zaman, A
|
|
1999
|
2 |
3 |
p. 202-
1 p.
|
artikel
|
| 83 |
Pharmacoeconomic Perspectives in Russia
|
Stratchounski, L.S.
|
|
1999
|
2 |
3 |
p. 246-248
3 p.
|
artikel
|
| 84 |
PHARMACOECONOMICS: OF SCREENING AND TESTING
|
Shih, YCT
|
|
1999
|
2 |
3 |
p. 231-
1 p.
|
artikel
|
| 85 |
PID4: A RETROSPECTIVE DATABASE STUDY OF AIDS INITIAL TREATMENT REGIMENS, SWITCHING PATTERNS, AND PATIENT ADHERENCE
|
Hutchison, S
|
|
1999
|
2 |
3 |
p. 183-
1 p.
|
artikel
|
| 86 |
PID7: COST-EFFECTIVE ANALYSIS OF ORAL ONYCHOMYCOSIS THERAPIES USING IDAHO MEDICAID CLAIMS DATA
|
Alemao, EA
|
|
1999
|
2 |
3 |
p. 184-
1 p.
|
artikel
|
| 87 |
PID1: COST-EFFECTIVENESS ANALYSIS OF RECOMBINANT HUMAN ERYTHROPOIETIN VERSUS TRANSFUSION IN HIV PATIENTS TREATED WITH ZIDOVUDINE
|
Juzba, M
|
|
1999
|
2 |
3 |
p. 182-
1 p.
|
artikel
|
| 88 |
PID11: COST-EFFECTIVENESS OF FIVE ORAL ANTIMICROBIALS FOR ACUTE OTITIS MEDIA
|
Kaplan-Machlis, B
|
|
1999
|
2 |
3 |
p. 186-
1 p.
|
artikel
|
| 89 |
PID19: COST-EFFECTIVENESS OF ONCE-DAILY CLARITHROMYCIN COMPARED TO AMOXYCILLIN/CLAVULANIC ACID IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
|
Hutton, J
|
|
1999
|
2 |
3 |
p. 189-
1 p.
|
artikel
|
| 90 |
PID17: DETERMINATION OF THE COST-EFFECTIVENESS OF A TUBERCULOSIS PREVENTION PROGRAM ALONG THE US/ MEXICO BORDER USING MARKOV PROCESS MODELING WITHIN A PREVENTION EFFECTIVENESS FRAMEWORK
|
Borrego, ME
|
|
1999
|
2 |
3 |
p. 188-
1 p.
|
artikel
|
| 91 |
PID5: DEVELOPMENT AND INITIAL ASSESSMENT OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE-7 FOR USE IN INTERNATIONAL HIV STUDIES
|
Metcalf, M
|
|
1999
|
2 |
3 |
p. 183-184
2 p.
|
artikel
|
| 92 |
PID10: DEVELOPMENT AND VALIDATION OF A DECISION ANALYTIC FRAMEWORK (DAF) TO EVALUATE THE ECONOMIC IMPACT OF SUSPECTED MENINGITIS (SM)
|
Parasuraman, TV
|
|
1999
|
2 |
3 |
p. 185-186
2 p.
|
artikel
|
| 93 |
PID14: ECONOMIC ANALYSIS OF ANTIMICROBIAL AGENTS FOR HOSPITAL-ACQUIRED PNEUMONIA
|
Wong, AH
|
|
1999
|
2 |
3 |
p. 187-
1 p.
|
artikel
|
| 94 |
PID3: ECONOMIC EVALUATION OF SYSTEMIC TREATMENTS FOR CMV RETINITIS IN PERSONS WITH AIDS IN SWITZERLAND
|
Lee, TA
|
|
1999
|
2 |
3 |
p. 183-
1 p.
|
artikel
|
| 95 |
PID16: ECONOMIC STUDY OF CEPHALOSPORINS IN THE TREATMENT OF MODERATE LOWER RESPIRATORY TRACT INFECTION
|
Zhigao, HE
|
|
1999
|
2 |
3 |
p. 187-188
2 p.
|
artikel
|
| 96 |
PID9: EVALUATION OF THE OUTCOMES OF PATIENTS ON HEMODIALYSIS RECEIVING AMPHOTERICIN B LIPID COMPLEX (ABLC)
|
Coley, KC
|
|
1999
|
2 |
3 |
p. 185-
1 p.
|
artikel
|
| 97 |
PID6: HEALTH-RELATED QUALITY OF LIFE CHANGES IN PATIENTS WITH ONYCHOMYCOSIS
|
Lubeck, DP
|
|
1999
|
2 |
3 |
p. 184-
1 p.
|
artikel
|
| 98 |
PID2: INCREASED COST OF MANAGING AIDS IN THE LAST YEAR OF LIFE
|
O'Brien, JA
|
|
1999
|
2 |
3 |
p. 182-183
2 p.
|
artikel
|
| 99 |
PID15: INFLUENCE OF MOTIVATING FACTORS AND BARRIERS ON INFLUENZA VACCINATION IN AN EMPLOYED POPULATION
|
Parasuraman, TV
|
|
1999
|
2 |
3 |
p. 187-
1 p.
|
artikel
|
| 100 |
PID13: LONG-TERM EFFICACY OF LOCAL GUIDELINES TO IMPROVE ANTITETANUS PROPHYLAXIS AND REDUCE COSTS IN AN EMERGENCY DEPARTMENT
|
Elkharrat, D
|
|
1999
|
2 |
3 |
p. 186-187
2 p.
|
artikel
|
| 101 |
PID20: SAVINGS IN DIRECT MEDICAL COSTS PRODUCED BY AN INHALED SOLUTION OF TOBRAMYCIN (TOBI) IN CHILDREN WITH CYSTIC FIBROSIS
|
LeLorier, J
|
|
1999
|
2 |
3 |
p. 189-
1 p.
|
artikel
|
| 102 |
PID18: THE COST OF INFLUENZA IN THE EMERGENCY ROOM AND HOSPITAL
|
Cox, FM
|
|
1999
|
2 |
3 |
p. 188-189
2 p.
|
artikel
|
| 103 |
PID12: THE RATE OF INFECTIONS CONCURRENT WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA
|
Shmuely, Y
|
|
1999
|
2 |
3 |
p. 186-
1 p.
|
artikel
|
| 104 |
PID8: TREATMENT OF ONYCHOMYCOSIS OF THE NAIL IN A MEDICAID POPULATION
|
Phatak, HM
|
|
1999
|
2 |
3 |
p. 184-185
2 p.
|
artikel
|
| 105 |
PKU5: ACUTE REJECTION EPISODES ARE ASSOCIATED WITH HIGHER UTILIZATION OF RESOURCES AFTER KIDNEY TRANSPLANTATION
|
Manninen, DL
|
|
1999
|
2 |
3 |
p. 204-
1 p.
|
artikel
|
| 106 |
PKU1: A METHOD FOR COMPARING DISPARATE OUTCOME MEASURES IN OVERACTIVE BLADDER CLINICAL TRIALS
|
Casciano, R
|
|
1999
|
2 |
3 |
p. 202-203
2 p.
|
artikel
|
| 107 |
PKU6: COST-EFFECTIVENESS ANALYSIS OF MYCOPHENOLATE MOFETIL TREATMENT FOR INTRACTABLE ACUTE REJECTION IN RENAL TRANSPLANTATION RECIPIENTS
|
Sakamaki, H
|
|
1999
|
2 |
3 |
p. 204-205
2 p.
|
artikel
|
| 108 |
PKU7: COST UTILITY ANALYSIS OF LIVER AND KIDNEY TRANSPLANTATION IN GERMANY
|
Greiner, W
|
|
1999
|
2 |
3 |
p. 205-
1 p.
|
artikel
|
| 109 |
PKU2: IMPROVEMENTS IN CLINICAL OUTCOMES, HEALTH-RELATED QUALITY OF LIFE (HRQoL) AND SYMPTOM BOTHER FOR OVERACTIVE BLADDER PATIENTS TREATED WITH A NEW ONCE-DAILY FORMULATION OF OXYBUTYNIN
|
Lubeck, D
|
|
1999
|
2 |
3 |
p. 203-
1 p.
|
artikel
|
| 110 |
PKU4: LINGUISTIC VALIDATION OF THE KING'S HEALTH QUESTIONNAIRE (KHQ) IN EIGHT LANGUAGES
|
Conway, K
|
|
1999
|
2 |
3 |
p. 204-
1 p.
|
artikel
|
| 111 |
PKU3: LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE
|
Conway, K
|
|
1999
|
2 |
3 |
p. 203-204
2 p.
|
artikel
|
| 112 |
PNP9: ANTIDEPRESSANT IMPACT ON SOCIAL FUNCTIONING: REBOXETINE VERSUS FLUOXETINE
|
Venditti, LN
|
|
1999
|
2 |
3 |
p. 171-172
2 p.
|
artikel
|
| 113 |
PNP16: ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA OVER A 2-YEAR PERIOD
|
McCombs, JS
|
|
1999
|
2 |
3 |
p. 174-
1 p.
|
artikel
|
| 114 |
PNP20: ANTIPSYCHOTIC UTILIZATION RATIOS: DIFFERENCES AMONG AGE, GENDER, AND PAYER COMBINATIONS
|
Hutchins, D
|
|
1999
|
2 |
3 |
p. 176-
1 p.
|
artikel
|
| 115 |
PNP14: COST AND UTILIZATION OUTCOMES OF PATIENTS TREATED FOR SCHIZOPHRENIA IN A MEDICAID POPULATION
|
Christensen, D
|
|
1999
|
2 |
3 |
p. 173-174
2 p.
|
artikel
|
| 116 |
PNP10: COST-BENEFIT ANALYSIS OF FLUOXETINE INCLUSION IN THE MEDI-CAL FORMULARY
|
Field, J
|
|
1999
|
2 |
3 |
p. 172-
1 p.
|
artikel
|
| 117 |
PNP6: COST-BENEFIT ANALYSIS OF ORAL ANTIDEPRESSANTS IN THE MANAGEMENT OF MAJOR DEPRESSIVE DISORDER: A MANAGED CARE PERSPECTIVE
|
Chen, P
|
|
1999
|
2 |
3 |
p. 170-
1 p.
|
artikel
|
| 118 |
PNP8: DEPRESSION IN POOR, YOUNG WOMEN: FLUOXETINE VERSUS SERTRALINE
|
Singer, ME
|
|
1999
|
2 |
3 |
p. 171-
1 p.
|
artikel
|
| 119 |
PNP1: DEVELOPMENT AND INITIAL VALIDATION OF A BRIEF MENTAL HEALTH OUTCOME MEASURE
|
Lenderking, WR
|
|
1999
|
2 |
3 |
p. 168-169
2 p.
|
artikel
|
| 120 |
PNP13: DEVELOPMENT OF A COST CONSEQUENCES COMPUTER SIMULATION MODEL OF BIPOLAR DISORDER
|
Mather, DB
|
|
1999
|
2 |
3 |
p. 173-
1 p.
|
artikel
|
| 121 |
PNP11: DIABETES MELLITUS AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS RECEIVING ANTIDEPRESSANT DRUGS
|
Taylor, AT
|
|
1999
|
2 |
3 |
p. 172-
1 p.
|
artikel
|
| 122 |
PNP12: DIRECT MEDICAL COST DIFFERENCES BETWEEN ALZHEIMER'S PATIENTS AND ELDERLY NON-ALZHEIMER'S PATIENTS IN A MANAGED CARE ORGANIZATION
|
Richards, KM
|
|
1999
|
2 |
3 |
p. 172-173
2 p.
|
artikel
|
| 123 |
PNP17: ECONOMIC BURDEN DUE TO COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE MANAGEMENT OF PSYCHIATRIC DISORDERS IN INDIA
|
Chaturvedi, SK
|
|
1999
|
2 |
3 |
p. 174-175
2 p.
|
artikel
|
| 124 |
PNP4: ECONOMIC OUTCOMES OF ANTIDEPRESSANT USE IN A MANAGED CARE ORGANIZATION
|
White, TJ
|
|
1999
|
2 |
3 |
p. 169-170
2 p.
|
artikel
|
| 125 |
PNP22: HYPNOTIC DRUGS CONSUMPTION IN RUSSIA
|
Gorkov, V
|
|
1999
|
2 |
3 |
p. 176-177
2 p.
|
artikel
|
| 126 |
PNP2: IMPACT OF CLINICIAN EDUCATION ON LONG-TERM ANTIDEPRESSANT PRESCRIBING
|
Fulop, G
|
|
1999
|
2 |
3 |
p. 169-
1 p.
|
artikel
|
| 127 |
PNP5: PHARMACOECONOMIC ANALYSIS OF PATTERNS OF ANTIDEPRESSANT USE
|
Egan, T
|
|
1999
|
2 |
3 |
p. 170-
1 p.
|
artikel
|
| 128 |
PNP19: PSYCHOTROPIC PRESCRIBING FOR THE ELDERLY IN AMBULATORY CLINICS
|
Aparasu, RR
|
|
1999
|
2 |
3 |
p. 175-176
2 p.
|
artikel
|
| 129 |
PNP3: RACIAL AND GENDER DIFFERENCES IN ACCESS TO A NEW DRUG THERAPY
|
Pinto, LA
|
|
1999
|
2 |
3 |
p. 169-
1 p.
|
artikel
|
| 130 |
PNP15: RETROSPECTIVE DATABASE ANALYSIS: ADJUSTMENTS REQUIRED FOR ANTIPSYCHOTIC DOSING AND DURATION PATTERNS
|
Booth, G
|
|
1999
|
2 |
3 |
p. 174-
1 p.
|
artikel
|
| 131 |
PNP7: SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) UTILIZATION PATTERNS IN PATIENTS WITH OR WITHOUT A DEPRESSION DIAGNOSIS
|
Brondum, J
|
|
1999
|
2 |
3 |
p. 170-171
2 p.
|
artikel
|
| 132 |
PNP21: THE ECONOMIC COSTS OF HEROIN ADDICTION
|
Mark, T
|
|
1999
|
2 |
3 |
p. 176-
1 p.
|
artikel
|
| 133 |
PNP23: THE IMPACT OF ALCOHOL CONSUMPTION AND SMOKING ON SHORT-TERM HEALTHCARE COSTS IN A MANAGED CARE POPULATION
|
Field, J
|
|
1999
|
2 |
3 |
p. 177-
1 p.
|
artikel
|
| 134 |
PNP18: USE OF ANTIPSYCHOTIC MEDICATIONS AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA
|
Johnstone, BM
|
|
1999
|
2 |
3 |
p. 175-
1 p.
|
artikel
|
| 135 |
POR9: CLINICAL EPIDEMIOLOGY PRINCIPLES OF AND THE COST OF DRUG TRIALS
|
Gorkov, V
|
|
1999
|
2 |
3 |
p. 220-
1 p.
|
artikel
|
| 136 |
POR7: DEVELOPING A QUALITY ASSESSMENT SCORING SYSTEM FOR ECONOMIC EVALUATIONS
|
Pang, F
|
|
1999
|
2 |
3 |
p. 219-
1 p.
|
artikel
|
| 137 |
POR3: EDMONTON QUALITY ASSESSMENT TOOL FOR DRUG UTILIZATION REVIEWS (EQATDUR): AN INSTRUMENT FOR ASSESSING THE METHODOLOGIC RIGOR OF DRUG UTILIZATION REVIEWS
|
Spooner, CH
|
|
1999
|
2 |
3 |
p. 218-
1 p.
|
artikel
|
| 138 |
POR5: EVALUATION OF THE ANALYTICAL HIERARCHY PROCESS (AHP) AS A TOOL IN FORMULARY DEVELOPMENT
|
Wilson, AE
|
|
1999
|
2 |
3 |
p. 218-219
2 p.
|
artikel
|
| 139 |
POR6: EVALUATION OF THE STRUCTURAL VALIDITY OF THE SF-12
|
Reed, PJ
|
|
1999
|
2 |
3 |
p. 219-
1 p.
|
artikel
|
| 140 |
POR4: LINGUISTIC VALIDATION OF THE SLICE/LIFE QUESTIONNAIRE
|
Conway, K
|
|
1999
|
2 |
3 |
p. 218-
1 p.
|
artikel
|
| 141 |
POR1: METHODOLOGY FOR DEVELOPING AN INDEX SCORE FOR BOTHERSOMENESS OF ADVERSE EVENTS
|
Becker, LA
|
|
1999
|
2 |
3 |
p. 217-
1 p.
|
artikel
|
| 142 |
POR8: MINIMAL STANDARDS FOR THE VALIDATION OF QUALITY OF LIFE INSTRUMENTS USED IN CLINICAL TRIALS
|
Chassany, O
|
|
1999
|
2 |
3 |
p. 219-220
2 p.
|
artikel
|
| 143 |
POR10: PREDICTING MARKET SHARES FOR NEW PHARMCEUTICAL PRODUCTS USING STATED PREFERENCES
|
Bingham, MF
|
|
1999
|
2 |
3 |
p. 220-
1 p.
|
artikel
|
| 144 |
POR2: PSYCHOMETRIC EVALUATION OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE
|
Jordan, J
|
|
1999
|
2 |
3 |
p. 217-218
2 p.
|
artikel
|
| 145 |
PPO8: AN EMPIRICAL ANALYSIS ON AMBULATORY CARE UTILIZATION: APPLICATION OF A COUNT DATA MODEL
|
Sengupta, N
|
|
1999
|
2 |
3 |
p. 215-
1 p.
|
artikel
|
| 146 |
PPO4: COMMUNITY PHARMACIST ASSESSMENT OF THE MOTIVATIONS FOR PROVIDING PHARMACEUTICAL CARE ACROSS FOUR DOMAINS
|
Spruill, WJ
|
|
1999
|
2 |
3 |
p. 213-214
2 p.
|
artikel
|
| 147 |
PPO3: DESIGNING A USER-FRIENDLY OUTCOMES RESEARCH DATABASE FOR THE PRIVATE MEDICAL PRACTITIONER
|
Sarpong, DF
|
|
1999
|
2 |
3 |
p. 213-
1 p.
|
artikel
|
| 148 |
PPO12: EFFECT OF PLAN CHARACTERISTICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM
|
Momin, SR
|
|
1999
|
2 |
3 |
p. 216-217
2 p.
|
artikel
|
| 149 |
PPO11: NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING: OVERVIEW OF THE PROCESS AND PRESENTATION OF DESCRIPTIVE STATISTICS
|
Jardina, P
|
|
1999
|
2 |
3 |
p. 216-
1 p.
|
artikel
|
| 150 |
PPO5: PHARMACIST ASSESSMENT OF THE VALUE OF PROVIDING PHARMACEUTICAL CARE IN THE COMMUNITY PHARMACY SETTING
|
Wade, WE
|
|
1999
|
2 |
3 |
p. 214-
1 p.
|
artikel
|
| 151 |
PPO2: THE DEVELOPMENT OF A PRACTICAL PROVIDER PROFILING REPORT
|
Gevirtz, F
|
|
1999
|
2 |
3 |
p. 212-213
2 p.
|
artikel
|
| 152 |
PPO1: THE ROLE OF QUALITY OF LIFE INFORMATION IN MANAGED CARE DECISION-MAKING
|
Crawford, B
|
|
1999
|
2 |
3 |
p. 212-
1 p.
|
artikel
|
| 153 |
PPO6: TIME-DEPENDENT SURVIVAL ANALYSIS OF A PHARMACIST'S CONSULTATION INTERVENTION STUDY
|
Yuan, Y
|
|
1999
|
2 |
3 |
p. 214-
1 p.
|
artikel
|
| 154 |
PPO10: UNDERSTANDING THE PROCESS AND ROLE OF TECHNOLOGY ASSESSMENT IN LARGE HEALTH MAINTENANCE ORGANIZATIONS
|
Wise, S
|
|
1999
|
2 |
3 |
p. 216-
1 p.
|
artikel
|
| 155 |
PPO9: USING OUTCOMES RESEARCH TO DEMONSTRATE QUALITY IMPROVEMENT FOR NCQA ACCREDITATION: A CASE STUDY
|
Way, K
|
|
1999
|
2 |
3 |
p. 215-216
2 p.
|
artikel
|
| 156 |
PPO7: UTILIZATION OF AMBULATORY CARE SERVICES DUE TO ADVERSE EFFECTS OF MEDICATIONS IN THE UNITED STATES
|
Aparasu, RR
|
|
1999
|
2 |
3 |
p. 214-215
2 p.
|
artikel
|
| 157 |
PPR7: A FORMAL AUDIT OF 228 PUBLISHED COST-UTILITY ANALYSES
|
Neumann, P
|
|
1999
|
2 |
3 |
p. 223-
1 p.
|
artikel
|
| 158 |
PPR6: COST-EFFECTIVENESS ANALYSIS: A SIMULTANEOUS MARGINAL-EFFECT APPROACH
|
Liu, G
|
|
1999
|
2 |
3 |
p. 222-223
2 p.
|
artikel
|
| 159 |
PPR4: DEVELOPING METHODOLOGICAL STANDARDS IN PHARMACOECONOMIC RESEARCH: AN APPROACH BY A TASK FORCE OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY
|
Hirschfeld, RMA
|
|
1999
|
2 |
3 |
p. 222-
1 p.
|
artikel
|
| 160 |
PPR5: ESTIMATING HEALTHCARE COSTS IN THE ABSENCE OF FINANCIAL DATA: A CASE STUDY
|
Russell, MW
|
|
1999
|
2 |
3 |
p. 222-
1 p.
|
artikel
|
| 161 |
PPR2: EVALUATION OF AN EDUCATIONAL INTERVENTION ON THE PERCEPTION OF COST-EFFECTIVE INFORMATION RELATIVE TO CLINICAL INFORMATION
|
Sarratt, D
|
|
1999
|
2 |
3 |
p. 221-
1 p.
|
artikel
|
| 162 |
PPR1: PRE-TEST OF A MARKOV MODEL TO ESTIMATE THE COST OF ILLNESS IN AMBULATORY PATIENTS: A PRELIMINARY ESTIMATE USING PHYSICIAN SURVEY DATA
|
Halberg, DL
|
|
1999
|
2 |
3 |
p. 221-
1 p.
|
artikel
|
| 163 |
PPR3: THE ROLE OF PHARMACOECONOMIC INVESTIGATIONS IN CREATING THE PATIENT'S TREATMENT RECORD
|
Vorobjev, PA
|
|
1999
|
2 |
3 |
p. 221-222
2 p.
|
artikel
|
| 164 |
PRD14: A PHARMACOECONOMIC EVALUATION OF BUDESONIDE AQUEOUS NASAL SPRAY AND FLUTICASONE PROPIONATE NASAL SPRAY IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS
|
Ståhl, E
|
|
1999
|
2 |
3 |
p. 181-182
2 p.
|
artikel
|
| 165 |
PRD8: A RETROSPECTIVE DATABASE STUDY OF PATIENT ADHERENCE WITH ASTHMA TREATMENT REGIMENS
|
Hutchison, S
|
|
1999
|
2 |
3 |
p. 179-180
2 p.
|
artikel
|
| 166 |
PRD2: A TELEPHONE-BASED APPROACH FOR MONITORING HEALTH STATUS IN ASTHMA DISEASE MANAGEMENT
|
Ricci, J
|
|
1999
|
2 |
3 |
p. 177-178
2 p.
|
artikel
|
| 167 |
PRD1: BARRIERS TO EFFECTIVE ASTHMA DISEASE MANAGEMENT: LIMITATIONS IN PHYSICIAN KNOWLEDGE OF TREATMENT GUIDELINES
|
Ricci, J
|
|
1999
|
2 |
3 |
p. 177-
1 p.
|
artikel
|
| 168 |
PRD4: COST BENEFIT ANALYSIS OF ASTHMA EDUCATION PROGRAMS
|
Liu, G
|
|
1999
|
2 |
3 |
p. 178-179
2 p.
|
artikel
|
| 169 |
PRD10: COST-EFFECTIVENESS OF AZITHROMYCIN AND CO-AMOXICLAV IN ACUTE SINUSITIS
|
Karpov, O
|
|
1999
|
2 |
3 |
p. 180-
1 p.
|
artikel
|
| 170 |
PRD12: DETERMINING THE CLINICAL RELEVANCE OF STATISTICALLY SIGNIFICANT IMPROVEMENTS IN QUALITY OF LIFE
|
Schleusener, D
|
|
1999
|
2 |
3 |
p. 181-
1 p.
|
artikel
|
| 171 |
PRD13: DEVELOPMENT OF A NASAL COMFORT INDEX FOR NASAL SPRAYS IN ADULTS WITH SEASONAL ALLERGIC RHINITIS
|
Keresteci, MA
|
|
1999
|
2 |
3 |
p. 181-
1 p.
|
artikel
|
| 172 |
PRD3: DEVELOPMENT OF AN ASTHMA QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE AMERICAN ADULTS (AQLQ-NAA)
|
Gupchup, GV
|
|
1999
|
2 |
3 |
p. 178-
1 p.
|
artikel
|
| 173 |
PRD11: QUALITY OF LIFE ASSESSMENT IN ALLERGIC RHINITIS PATIENTS TREATED WITH LORATADINE
|
Hauser, R
|
|
1999
|
2 |
3 |
p. 180-181
2 p.
|
artikel
|
| 174 |
PRD5: THE FIRST PHARMACOECONOMIC STUDY IN ASTHMA: SOME IMPORTANT OBSERVATIONS
|
Andersson, F
|
|
1999
|
2 |
3 |
p. 179-
1 p.
|
artikel
|
| 175 |
PRD9: THE HEALTHCARE UTILIZATION OF PATIENTS WITH CHRONIC SINUSITIS
|
Edelman-Lewis, B
|
|
1999
|
2 |
3 |
p. 180-
1 p.
|
artikel
|
| 176 |
PRD7: THE USE OF GENERALIZED ESTIMATING EQUATIONS IN LONGITUDINAL STUDIES OF RESOURCE UTILIZATION: THE CASE OF ASTHMA
|
Itzler, RF
|
|
1999
|
2 |
3 |
p. 179-
1 p.
|
artikel
|
| 177 |
PUP3: ANALYSIS OF THE ECONOMIC IMPACT OF AN INCREASE IN THE UTILIZATION OF GENERIC MEDICATIONS IN PORTUGAL
|
Vilas-Boas, IM
|
|
1999
|
2 |
3 |
p. 224-
1 p.
|
artikel
|
| 178 |
PUP5: ECONOMIC IMPACT OF PRESCRIBING IN THE URBAN COMMUNITY OF DELHI
|
Bapna, JS
|
|
1999
|
2 |
3 |
p. 225-
1 p.
|
artikel
|
| 179 |
PUP4: IMPLEMENTATION OF PHARMACOECONOMIC ANALYSIS IN NORWAY. ARE THE USERS PREPARED?
|
Rorvik, EM
|
|
1999
|
2 |
3 |
p. 224-225
2 p.
|
artikel
|
| 180 |
PUP2: PHARMACOECONOMIC INFORMATION IN FORMULARY DECISION-MAKING IN THE UNITED STATES
|
Evans, C
|
|
1999
|
2 |
3 |
p. 224-
1 p.
|
artikel
|
| 181 |
PUP1: PHARMACOECONOMICS IN RUSSIA: FIRST STEPS
|
Moisseyev, S
|
|
1999
|
2 |
3 |
p. 223-224
2 p.
|
artikel
|
| 182 |
PWM1: COMPARATIVE CLINICAL ECONOMICS OF THE INTRAUTERINE LEVONORGESTRELRELEASING SYSTEM MIRENA IN WOMEN REQUIRING CONTRACEPTION
|
Milne, RJ
|
|
1999
|
2 |
3 |
p. 209-
1 p.
|
artikel
|
| 183 |
PWM5: COMPARISON OF QUALITY OF LIFE SCORES BETWEEN MENOPAUSAL WOMEN AND AGEMATCHED PEERS
|
Keininger, DL
|
|
1999
|
2 |
3 |
p. 210-211
2 p.
|
artikel
|
| 184 |
PWM7: COST-EFFECTIVENESS OF ESTROGEN REPLACEMENT THERAPY (ERT) ON THE PREVENTION OF OSTEOPOROSIS: SHORT-TERM VERSUS LONG-TERM THERAPY
|
Liu, G
|
|
1999
|
2 |
3 |
p. 211-
1 p.
|
artikel
|
| 185 |
PWM8: COST-EFFECTIVENESS OF VIAGRA VERSUS MUSE IN THE TREATMENT OF MALE ERECTILE DYSFUNCTION
|
Liu, G
|
|
1999
|
2 |
3 |
p. 211-212
2 p.
|
artikel
|
| 186 |
PWM9: ECONOMIC EVALUATION IN REAL-LIFE SETTING OF ALPHA-BLOCKERS VERSUS FINASTERIDE VERSUS SERENOA REPENS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
|
Schmitt, C
|
|
1999
|
2 |
3 |
p. 212-
1 p.
|
artikel
|
| 187 |
PWM2: EFFECTIVENESS AND COST IMPACT OF EMERGENCY CONTRACEPTION OBTAINED FROM A PHARMACIST IN WASHINGTON STATE
|
Marciante, KD
|
|
1999
|
2 |
3 |
p. 209-
1 p.
|
artikel
|
| 188 |
PWM6: IMPACT OF POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY ON RESOURCE UTILIZATION ASSOCIATED WITH ADVERSE EVENTS
|
Chawla, AJ
|
|
1999
|
2 |
3 |
p. 211-
1 p.
|
artikel
|
| 189 |
PWM3: IMPLICATIONS OF MENOPAUSAL SYMPTOMS ON QUALITY OF LIFE
|
Girod, I
|
|
1999
|
2 |
3 |
p. 209-210
2 p.
|
artikel
|
| 190 |
PWM4: THE RELATIONSHIP BETWEEN NOTTINGHAM HEALTH PROFILE DOMAINS AND CLINICAL CHARACTERISTICS OF WOMEN WITH ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS
|
Foster, SA
|
|
1999
|
2 |
3 |
p. 210-
1 p.
|
artikel
|
| 191 |
RD2: COST-EFFICACY ANALYSIS OF AN INHALED CORTICOSTEROID VERSUS A LEUKOTRIENE RECEPTOR ANTAGONIST
|
Carranza-Rosenzweig, JR
|
|
1999
|
2 |
3 |
p. 132-133
2 p.
|
artikel
|
| 192 |
RD3: CYSTIC FIBROSIS: AGGRESSIVE INTERVENTION IS ASSOCIATED WITH IMPROVED OUTCOME
|
Johnson, C
|
|
1999
|
2 |
3 |
p. 133-
1 p.
|
artikel
|
| 193 |
RD4: RELATIONSHIP AMONG DISEASE-SPECIFIC QUALITY OF LIFE AND CLINICAL CONSEQUENCES OF ASTHMA
|
Kozma, CM
|
|
1999
|
2 |
3 |
p. 133-
1 p.
|
artikel
|
| 194 |
RD1: TREATING ALLERGIC RHINITIS IN PATIENTS WITH COMORBID ASTHMA: THE RISK OF ASTHMA-RELATED HOSPITALIZATIONS AND EMERGENCY ROOM VISITS
|
Crystal-Peters, J
|
|
1999
|
2 |
3 |
p. 132-
1 p.
|
artikel
|
| 195 |
RM1: CONTROLLING FOR SIMULTANEITY BIAS IN OUTCOME STUDIES USING PANEL DATA
|
Luo, R
|
|
1999
|
2 |
3 |
p. 137-
1 p.
|
artikel
|
| 196 |
RM2: COSTS OF HEALTHCARE FOR 8 YEARS PRIOR TO RECOGNITION OF TYPE 2 DIABETES (DM2)
|
Nichols, GA
|
|
1999
|
2 |
3 |
p. 137-
1 p.
|
artikel
|
| 197 |
RM4: OUTCOME ASSESSMENT OF A FALL RISK-REDUCTION PROGRAM: METHODOLOGICAL ISSUES
|
Maynard, PW
|
|
1999
|
2 |
3 |
p. 138-
1 p.
|
artikel
|
| 198 |
RM3: THE USE OF ABCIXIMAB FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PATIENTS ENROLLED IN MANAGED CARE ORGANIZATIONS
|
Lage, M
|
|
1999
|
2 |
3 |
p. 137-138
2 p.
|
artikel
|
| 199 |
TPCP7: A PATH ANALYTIC STUDY OF THE ASSOCIATION BETWEEN PHARMACISTS' DIRECTIVE GUIDANCE BEHAVIORS, PATIENT SATISFACTION, PATIENT COMPLIANCE, AND HEALTH-RELATED QUALITY OF LIFE (HRQoL)
|
Singhal, PK
|
|
1999
|
2 |
3 |
p. 149-150
2 p.
|
artikel
|
| 200 |
TPCP4: DISCRETE CHOICE MODELING ON PATIENT PERCEIVED COMPLIANCE: ANALYSIS OF PATIENT'S HEALTH BELIEF PERSPECTIVE
|
Sengupta, N
|
|
1999
|
2 |
3 |
p. 148-
1 p.
|
artikel
|
| 201 |
TPCP3: PATIENT COMPLIANCE, QUALITY OF LIFE, AND SATISFACTION AFTER INTENSIVE OUTPATIENT COUNSELING
|
Juzba, M
|
|
1999
|
2 |
3 |
p. 148-
1 p.
|
artikel
|
| 202 |
TPCP2: PERCENTAGE OF ANTI-HYPERTENSIVE DRUGS “FILLED AS INTENDED” COMPARING PHARMACY CLAIMS AND MEDICAL RECORDS DATA
|
Connors, H
|
|
1999
|
2 |
3 |
p. 147-148
2 p.
|
artikel
|
| 203 |
TPCP5: THE COST OF DISCONTINUATION OF ANTI-HYPERTENSIVE DRUG THERAPY IN A MEDICAID POPULATION
|
Venturini, F
|
|
1999
|
2 |
3 |
p. 148-149
2 p.
|
artikel
|
| 204 |
TPCP6: THE ROLE OF ALTERNATIVE ANTIHYPERLIPIDEMIC DRUGS: PATIENT COMPLIANCE, HEALTHCARE UTILIZATION, AND HEALTHCARE COSTS
|
Shi, L
|
|
1999
|
2 |
3 |
p. 149-
1 p.
|
artikel
|
| 205 |
TPCP1: THE ROLE OF COMPLIANCE IN THERAPY CHANGES AMONG NEWLY DIAGNOSED DIABETIC PATIENTS
|
Cox, ER
|
|
1999
|
2 |
3 |
p. 147-
1 p.
|
artikel
|
| 206 |
TPCT7: CEFPODOXIME PROXETIL 100mg VERSUS CEFPODOXIME PROXETIL 200mg IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS IN ADULT PATIENTS
|
Wilson, JP
|
|
1999
|
2 |
3 |
p. 155-
1 p.
|
artikel
|
| 207 |
TPCT2: COST-EFFECTIVENESS OF ABCIXIMAB IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS: RESULTS FROM A META-ANALYSIS
|
Mauskopf, JA
|
|
1999
|
2 |
3 |
p. 153-
1 p.
|
artikel
|
| 208 |
TPCT3: COST-EFFECTIVENESS OF ANTIMALARIAL TREATMENT OF QUININE PLUS DOXYCYCLINE VERSUS ARTEMISININ PLUS DOXYCYCLINE IN PHUOC LONG HOSPITAL, VIETNAM
|
Sooksriwong, C
|
|
1999
|
2 |
3 |
p. 153-
1 p.
|
artikel
|
| 209 |
TPCT4: COST-EFFECTIVENESS OF RABEPRAZOLE VERSUS RANITIDINE IN REFLUX ESOPHAGITIS
|
Ofman, JJ
|
|
1999
|
2 |
3 |
p. 154-
1 p.
|
artikel
|
| 210 |
TPCT1: ECONOMIC ANALYSIS OF TIRILAZAD MESYLATE FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE: ECONOMIC EVALUATION COMBINING FOUR PHASE III CLINICAL TRIALS
|
Polsky, D
|
|
1999
|
2 |
3 |
p. 152-153
2 p.
|
artikel
|
| 211 |
TPCT6: INCREASED UPPER GASTROINTESTINAL (UGI) DISTRESS AMONG ARTHRITIS PATIENTS TREATED WITH NSAIDS AS COMPARED TO CELECOXIB AND PLACEBO
|
Burke, TA
|
|
1999
|
2 |
3 |
p. 154-155
2 p.
|
artikel
|
| 212 |
TPCT5: TREATMENT OF DIABETIC FOOT ULCERS WITH TOPICAL RECOMBINANT GROWTH FACTOR GEL ACHIEVES HIGHER HEALING RATES AND RESULTS IN LOWER PROJECTED COSTS OF CARE
|
Martens, L
|
|
1999
|
2 |
3 |
p. 154-
1 p.
|
artikel
|
| 213 |
TPDM1: ASSESSING THE PREDICTIVE ABILITY OF A DETERMINISTIC MODEL AND STOCHASTIC MODEL
|
Krueger, KP
|
|
1999
|
2 |
3 |
p. 150-
1 p.
|
artikel
|
| 214 |
TPDM5: COST-BENEFIT ANALYSIS OF AN INTRAUTERINE LEVONORGESTREL-RELEASING DEVICE MIRENA VERSUS HYSTERECTOMY FOR WOMEN WITH MENORRHAGIA
|
Milne, RJ
|
|
1999
|
2 |
3 |
p. 151-152
2 p.
|
artikel
|
| 215 |
TPDM2: COST-EFFECTIVENESS OF INCREASING WARFARIN USAGE FOR STROKE PROPHYLAXIS IN PATIENTS WITH ATRIAL FIBRILLATION
|
Touchette, DR
|
|
1999
|
2 |
3 |
p. 150-
1 p.
|
artikel
|
| 216 |
TPDM7: COST OF ISCHEMIC STROKE TREATMENT BY FUNCTIONAL STATUS: A MODEL COMPARING CITICOLINE TO STANDARD CARE
|
Wilson, DA
|
|
1999
|
2 |
3 |
p. 152-
1 p.
|
artikel
|
| 217 |
TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER
|
Arikian, SA
|
|
1999
|
2 |
3 |
p. 152-
1 p.
|
artikel
|
| 218 |
TPDM3: IS THERE POTENTIAL BIAS IN MODELING WITH DECISION ANALYTIC SOFTWARE OR MATRIX PROGRAMMING?
|
Nichol, G
|
|
1999
|
2 |
3 |
p. 150-151
2 p.
|
artikel
|
| 219 |
TPDM4: MODELING LIFETIME TREATMENT COSTS OF HIV/AIDS PATIENTS
|
Pleil, AM
|
|
1999
|
2 |
3 |
p. 151-
1 p.
|
artikel
|
| 220 |
TPIC2: IMPACT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD): A SURVEY OF PRIMARY CAREGIVERS
|
Jackson, SE
|
|
1999
|
2 |
3 |
p. 161-
1 p.
|
artikel
|
| 221 |
TPIC1: INDIRECT COSTS OF MIGRAINEURS: THREE DIFFERENT APPROACHES TO VALUING LOST WORKPLACE PRODUCTIVITY
|
Thornhill, JC
|
|
1999
|
2 |
3 |
p. 161-
1 p.
|
artikel
|
| 222 |
TPIC4: QUANTIFICATION OF INDIRECT BENEFITS FROM MORBIDITY AND MORTALITY REDUCTION: APPLICATION TO PHARMACY SERVICES PROGRAM EVALUATION
|
Lai, L
|
|
1999
|
2 |
3 |
p. 162-
1 p.
|
artikel
|
| 223 |
TPIC5: TELEPHONY AS A COST-EFFICIENT METHOD FOR ASSESSING HEALTHCARE UTILIZATION (HCU) AND PRODUCTIVITY LOSS (PL) IN AN EMPLOYED POPULATION
|
Parasuraman, TV
|
|
1999
|
2 |
3 |
p. 162-
1 p.
|
artikel
|
| 224 |
TPIC3: THE PRODUCTIVITY COSTS OF ALLERGIC RHINITIS
|
Crystal-Peters, J
|
|
1999
|
2 |
3 |
p. 161-162
2 p.
|
artikel
|
| 225 |
TPIL1: ANALYSIS OF DIRECT, INDIRECT, AND TOTAL COSTS OF ASTHMA FROM PATIENT SURVEY DATA
|
Johnson, KA
|
|
1999
|
2 |
3 |
p. 142-
1 p.
|
artikel
|
| 226 |
TPIL6: ESTIMATING THE ECONOMIC IMPACT (EI) OF VIRAL MENINGITIS (VM) IN THE UNITED STATES (US)
|
Parasuraman, TV
|
|
1999
|
2 |
3 |
p. 143-144
2 p.
|
artikel
|
| 227 |
TPIL5: EVALUATION OF MEDICAL RESOURCE UTILIZATION IN ALZHEIMER'S DISEASE
|
Morris, LS
|
|
1999
|
2 |
3 |
p. 143-
1 p.
|
artikel
|
| 228 |
TPIL7: MEDICAL RESOURCE USE AND PAYER COSTS OF INPATIENT AND OUTPATIENT CARE RELATED TO EPILEPSY
|
Griffiths, RI
|
|
1999
|
2 |
3 |
p. 144-
1 p.
|
artikel
|
| 229 |
TPIL4: SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP): INITIAL FINDINGS ON HEALTHCARE RESOURCE UTILIZATION IN AUSTRALIA
|
Gibson, J
|
|
1999
|
2 |
3 |
p. 143-
1 p.
|
artikel
|
| 230 |
TPIL2: THE COST OF TREATING PARKINSON'S DISEASE (PD) IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
|
McCombs, JS
|
|
1999
|
2 |
3 |
p. 142-
1 p.
|
artikel
|
| 231 |
TPIL3: THE MEDICAL COST OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS: METHODS AND EVIDENCE
|
Lee, DW
|
|
1999
|
2 |
3 |
p. 142-143
2 p.
|
artikel
|
| 232 |
TPQL5: A REVIEW AND EVALUATION OF THE EMEA DOCUMENTS WITH REFERENCE TO QUALITY OF LIFE (QOL) ASSESSMENT.
|
Apolone, G
|
|
1999
|
2 |
3 |
p. 157-
1 p.
|
artikel
|
| 233 |
TPQL4: A TIME SERIES AND PANEL DATA APPROACH TO CROSS-TRANSLATE DESCRIPTIVE HEALTH STATUS TO HEALTH PREFERENCE IN PATIENTS WITH CHRONIC DISEASES
|
Nishan, S
|
|
1999
|
2 |
3 |
p. 156-157
2 p.
|
artikel
|
| 234 |
TPQL1: DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE IN URINARY INCONTINENCE (CONTILIFE®)
|
Girod, I
|
|
1999
|
2 |
3 |
p. 155-156
2 p.
|
artikel
|
| 235 |
TPQL3: QUALITY OF LIFE IN CROHN DISEASE: A PROSPECTIVE, LONGITUDINAL STUDY IN 231 PATIENTS
|
Chircop, C
|
|
1999
|
2 |
3 |
p. 156-
1 p.
|
artikel
|
| 236 |
TPQL2: SF-36 AS A PREDICTOR OF HEALTH STATES
|
Reed, PJ
|
|
1999
|
2 |
3 |
p. 156-
1 p.
|
artikel
|
| 237 |
TPQL7: THE EFFECT OF ORDER OF ADMINISTRATION OF GENERIC AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRES
|
Lee, TA
|
|
1999
|
2 |
3 |
p. 158-
1 p.
|
artikel
|
| 238 |
TPQL6: THE PERFORMANCE OF A GENERIC MEASURE (EQ-5D) IN ASSESSING MENTAL HEALTH OUTCOMES
|
Kind, P
|
|
1999
|
2 |
3 |
p. 157-158
2 p.
|
artikel
|
| 239 |
TPRD7: ESTIMATING LIFE-EXPECTANCY IN POSTACUTE CORONARY SYNDROMES: THE IMPORTANCE OF TWO-COMPONENT SURVIVAL MODELS
|
Nelson, CL
|
|
1999
|
2 |
3 |
p. 160-161
2 p.
|
artikel
|
| 240 |
TPRD2: INCIDENCE OF SMALL-BOWEL OBSTRUCTION AND ADHESIOLYSIS FOLLOWING OPEN COLORECTAL AND GENERAL SURGERY
|
Beck, DE
|
|
1999
|
2 |
3 |
p. 158-159
2 p.
|
artikel
|
| 241 |
TPRD3: OUTCOMES OF TREATMENT OF UNCOMPLICATED HYPERTENSION WITH DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS
|
Lenert, LA
|
|
1999
|
2 |
3 |
p. 159-
1 p.
|
artikel
|
| 242 |
TPRD1: PHARMACOECONOMIC ANALYSIS OF WARFARIN VERSUS ENOXAPARIN USED PROPHYLACTICALLY IN HIP SURGERY
|
Egan, T
|
|
1999
|
2 |
3 |
p. 158-
1 p.
|
artikel
|
| 243 |
TPRD4: THE COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
|
Clark, T
|
|
1999
|
2 |
3 |
p. 159-
1 p.
|
artikel
|
| 244 |
TPRD6: TOTAL HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MIGRAINE IN A MEDICAID POPULATION
|
Joish, VN
|
|
1999
|
2 |
3 |
p. 160-
1 p.
|
artikel
|
| 245 |
TPRD5: USING HOSPITAL CLAIMS TO TRACK PRACTICE PATTERNS, OUTCOMES, AND COSTS IN PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
|
Karweit, J
|
|
1999
|
2 |
3 |
p. 159-160
2 p.
|
artikel
|
| 246 |
TPS1: A COST-EFFECTIVE APPROACH FOR UNIVERSAL COLON CANCER SCREENING IN A MANAGED CARE MODEL
|
Sampson, JM
|
|
1999
|
2 |
3 |
p. 144-145
2 p.
|
artikel
|
| 247 |
TPS4: COMPARISON OF THE EFFECTIVENESS OF INNOVATIVE PROGRAMS TO ENHANCE MAMMOGRAPHY COMPLIANCE: A META-ANALYSIS
|
Wu, H
|
|
1999
|
2 |
3 |
p. 145-146
2 p.
|
artikel
|
| 248 |
TPS2: COST ANALYSIS OF A DIAGNOSTIC SCREENING TO DIFFERENTIATE 30- TO 45-YEAR-OLD PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS
|
Kilburg, A
|
|
1999
|
2 |
3 |
p. 145-
1 p.
|
artikel
|
| 249 |
TPS5: COST-EFFECTIVENESS ANALYSIS OF GENETIC TESTING FOR BREAST CANCER
|
Luo, M
|
|
1999
|
2 |
3 |
p. 146-
1 p.
|
artikel
|
| 250 |
TPS6: COST-EFFECTIVENESS OF SCREENING AND TREATING DIABETIC RETINOPATHY IN TYPE I DIABETICS
|
Liu, G
|
|
1999
|
2 |
3 |
p. 146-
1 p.
|
artikel
|
| 251 |
TPS3: ESTIMATING THE VALUE OF DOUBLE READING IN MAMMOGRAPHY SCREENING
|
Semroc, GN
|
|
1999
|
2 |
3 |
p. 145-
1 p.
|
artikel
|
| 252 |
TPS7: PREVENTION OF RUBELLA INFECTION IN CRUISE SHIP CREW MEMBERS: A COST ANALYSIS COMPARING TWO INTERVENTIONS
|
Burnett, CL
|
|
1999
|
2 |
3 |
p. 146-147
2 p.
|
artikel
|
| 253 |
WDM3: APPLYING PRACTICAL APPLICATIONS OF PHARMACOECONOMICS AND OUTCOMES e DATA IN THE COMMUNITY HEALTHCARE FACILITY
|
Santorello, JG
|
|
1999
|
2 |
3 |
p. 236-237
2 p.
|
artikel
|
| 254 |
WDM1: CURRENT COMPUTER SOFTWARE AND HARDWARE OPTIONS IN PHARMACOECONOMICS: SPREADSHEETS, DECISION ANALYSIS, INTERNET, AND EDUCATIONAL TOOLS
|
McGhan, WF
|
|
1999
|
2 |
3 |
p. 228-
1 p.
|
artikel
|
| 255 |
WDM2: EXPERIENCE WITH RESEARCH DATA
|
Jackson, B
|
|
1999
|
2 |
3 |
p. 232-
1 p.
|
artikel
|
| 256 |
WMD4: COMBINING MARKET DATA AND STATEDPREFERENCE DATA TO ESTIMATE DEMAND FOR A NEW PHARMACEUTICAL
|
Johnson, FR
|
|
1999
|
2 |
3 |
p. 238-
1 p.
|
artikel
|
| 257 |
WMD1: DATA COLLECTION METHODS FOR RESOURCE UTILIZATION: CHOOSING THE RIGHT APPROACH
|
Crawford, B
|
|
1999
|
2 |
3 |
p. 229-230
2 p.
|
artikel
|
| 258 |
WMD3: NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING: PROCESS AND TECHNOLOGY
|
Jardina, P
|
|
1999
|
2 |
3 |
p. 234-
1 p.
|
artikel
|
| 259 |
WMD3: NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING: PROCESS AND TECHNOLOGY
|
Jardina, P
|
|
1999
|
2 |
3 |
p. 238-
1 p.
|
artikel
|
| 260 |
WMD2: THE WHAT, HOW, AND WHY OF THE DELPHI
|
Downs, K
|
|
1999
|
2 |
3 |
p. 234-
1 p.
|
artikel
|
| 261 |
WMM2: ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH
|
Hux, M
|
|
1999
|
2 |
3 |
p. 229-
1 p.
|
artikel
|
| 262 |
WMM1: IS THE CURRENT RELIANCE ON THE MARKOV ASSUMPTION IN ECONOMIC MODELS JUSTIFIED?
|
Caro, JJ
|
|
1999
|
2 |
3 |
p. 228-229
2 p.
|
artikel
|
| 263 |
WMM3: MODELING SEQUENTIAL DECISION-MAKING IN PHARMACOECONOMICS
|
Bala, MV
|
|
1999
|
2 |
3 |
p. 233-
1 p.
|
artikel
|
| 264 |
WMM5: USING EPIDEMIOLOGIC DATABASES TO EXTRAPOLATE LONG-TERM OUTCOMES FROM SURROGATE MARKER DATA
|
Huse, DM
|
|
1999
|
2 |
3 |
p. 237-
1 p.
|
artikel
|
| 265 |
WMQ2: A GUIDE FOR SELECTING HEALTH OUTCOMES AND QUALITY OF LIFE MEASURES
|
Erickson, P
|
|
1999
|
2 |
3 |
p. 234-235
2 p.
|
artikel
|
| 266 |
WMQ3: EVALUATING HIV DISEASE HEALTH OUTCOMES IN DIFFERENT TREATMENT SETTINGS: HOW TO SELECT THE MOST APPROPRIATE HRQL INSTRUMENT
|
Berzon, RA
|
|
1999
|
2 |
3 |
p. 239-
1 p.
|
artikel
|
| 267 |
WMQ1: THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM HEALTH QUESTIONNAIRE (SCAP-HQ): A BRIEF INSTRUMENT TO ASSESS OUTCOMES OF CARE IN SCHIZOPHRENIA
|
Johnstone, BM
|
|
1999
|
2 |
3 |
p. 230-
1 p.
|
artikel
|
| 268 |
WMS5: ASSESSING THE GENERALIZABILITY OF THE RESULTS OF MULTINATIONAL TRIALS FOR INDIVIDUAL COUNTRIES PARTICIPATING IN THE TRIAL
|
Glick, H
|
|
1999
|
2 |
3 |
p. 237-238
2 p.
|
artikel
|
| 269 |
WMS1: ESTIMATING MEDICAL COSTS FROM INCOMPLETE FOLLOW-UP DATA
|
Polsky, D
|
|
1999
|
2 |
3 |
p. 229-
1 p.
|
artikel
|
| 270 |
WMS2: PITFALLS WHEN USING REGRESSION EQUATIONS TO ESTIMATE TREATMENT IMPACT IN ACTUAL PRACTICE
|
Caro, JJ
|
|
1999
|
2 |
3 |
p. 237-
1 p.
|
artikel
|
| 271 |
WMS3: SOFTWARE FOR COST-EFFECTIVENESS STATISTICAL INFERENCE
|
Obenchain, R
|
|
1999
|
2 |
3 |
p. 233-
1 p.
|
artikel
|
| 272 |
WMS4: STATISTICAL ISSUES IN THE DESIGNING AND ANALYZING THE DATA FOR PHARMACOECONOMICS AND OUTCOME STUDIES
|
Rajagopalan, R
|
|
1999
|
2 |
3 |
p. 233-234
2 p.
|
artikel
|
| 273 |
WPE5: ANALYSES OF OUTCOME DOMAINS IN SCHIZOPHRENIA: METHODOLOGIES AND RESULTS FROM THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)
|
Russo, P
|
|
1999
|
2 |
3 |
p. 231-
1 p.
|
artikel
|
| 274 |
WPE4: AN ELECTRONIC TOOL FOR EMPIRIC ASSESSMENT OF DISEASE RISK, CATEGORIZATION OF PATIENTS AT RISK AND MONITORING OF OUTCOMES
|
Ambegaonkar, A
|
|
1999
|
2 |
3 |
p. 230-231
2 p.
|
artikel
|
| 275 |
WPE9: BEGIN WITH THE END IN MIND: ISSUES IN PLANNING PHARMACOECONOMIC RESEARCH FOR MORE EFFECTIVE COMMUNICATION
|
Rindress, D
|
|
1999
|
2 |
3 |
p. 227-
1 p.
|
artikel
|
| 276 |
WPE8: DESIGNING NATURALISTIC OUTCOMES TRIALS THAT ARE APPLICABLE TO THE “REAL WORLD” OF CLINICAL PRACTICE
|
Tunis, SL
|
|
1999
|
2 |
3 |
p. 235-
1 p.
|
artikel
|
| 277 |
WPE10: GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS: CURRENT USE AND EMERGING TRENDS
|
Munro, V
|
|
1999
|
2 |
3 |
p. 235-236
2 p.
|
artikel
|
| 278 |
WPE3: HEALTH ECONOMISTS AND MANAGED CARE DECISION-MAKERS: BRIDGING THE GAP
|
Bala, MV
|
|
1999
|
2 |
3 |
p. 227-
1 p.
|
artikel
|
| 279 |
WPE1: MODELING FOR POLICY-MAKERS THE EXPECTED BENEFITS OF PREVENTION
|
Leader, S
|
|
1999
|
2 |
3 |
p. 226-
1 p.
|
artikel
|
| 280 |
WPE7: SCHIZOPHRENIA: HELPING THE DECISIONMAKER TO UNDERSTAND THE IMPACTS OF ATYPICAL ANTIPSYCHOTICS
|
Mauskopf, J
|
|
1999
|
2 |
3 |
p. 235-
1 p.
|
artikel
|
| 281 |
WPE2: THE NUTS AND BOLTS OF CONDUCTING RANDOMIZED OUTCOMES TRIALS
|
Menzin, J
|
|
1999
|
2 |
3 |
p. 226-
1 p.
|
artikel
|
| 282 |
WTG1: APPLES AND APPLES, APPLES AND ORANGES: THE USE AND ABUSE OF AVERAGE DAILY DOSE IN PHARMACOECONOMIC RESEARCH
|
Loosbrock, D
|
|
1999
|
2 |
3 |
p. 227-228
2 p.
|
artikel
|
| 283 |
WTG4: ECONOMIC EVALUATION OF PHARMACEUTICALS IN ISRAEL: CURRENT AND FUTURE NATIONAL POLICY
|
Shani, S
|
|
1999
|
2 |
3 |
p. 232-
1 p.
|
artikel
|
| 284 |
WTG5: EVALUATION OF FORMULARY DECISIONS: PROJECTED IMPACT OF A NEW DRUG ROLLOUT WITHIN THE MANAGED CARE ARENA
|
Wright, A
|
|
1999
|
2 |
3 |
p. 236-
1 p.
|
artikel
|
| 285 |
WTG6: MAKING DECISIONS ABOUT ANTIBIOTIC RESISTANCE
|
Davey, PG
|
|
1999
|
2 |
3 |
p. 228-
1 p.
|
artikel
|
| 286 |
WTG2: UPDATE ON THE SCRIPT PROJECT
|
Westrick, E
|
|
1999
|
2 |
3 |
p. 236-
1 p.
|
artikel
|
| 287 |
WTG3: WHAT EVERY OUTCOMES RESEARCHER SHOULD KNOW ABOUT WOMEN'S HEALTH RESEARCH
|
Frank, L
|
|
1999
|
2 |
3 |
p. 231-232
2 p.
|
artikel
|
Tijdschrift beschrijving